General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Here's why you should buy these 3 stocks and hold them forever | finbold.com • |
Here's why you should buy these 3 stocks and hold them forever- Finance in Bold | news.google.com • |
Johnson & Johnson (NYSE:JNJ) Rating Reiterated by Cantor Fitzgerald | news.google.com • |
(JNJ) Investment Report | news.google.com • |
Why Johnson & Johnson (JNJ) is a Great Dividend Stock Right Now | news.google.com • |
Johnson & Johnson (NYSE:JNJ) Holdings Decreased by Summit Financial LLC | news.google.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-04-16 | 2024-03 | 2.64 | 2.71 | 0.07 | 2.65% |
2024-01-23 | 2023-12 | 2.27 | 2.29 | 0.02 | 0.88% |
2023-10-17 | 2023-09 | 2.52 | 2.66 | 0.14 | 5.56% |
2023-07-20 | 2023-06 | 2.61 | 2.8 | 0.19 | 7.28% |
2023-04-18 | 2023-03 | 2.51 | 2.68 | 0.17 | 6.77% |
2023-01-24 | 2022-12 | 2.22 | 2.35 | 0.13 | 5.86% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-10-17 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-10-17 | Raymond James | Upgrade | Outperform | Outperform |
2023-10-17 | Morgan Stanley | Upgrade | Equal-Weight | Equal-Weight |
2023-10-11 | Barclays | Upgrade | Equal-Weight | Equal-Weight |
2023-10-10 | Morgan Stanley | Upgrade | Equal-Weight | Equal-Weight |
2023-10-10 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-03-12 | BROADHURST VANESSA | Officer | 15.04K | Sale |
2024-02-12 | DECKER ROBERT J | Officer | 19.70K | Conversion of Exercise of derivative security |
2024-02-12 | DUATO JOAQUIN BOIX | Chief Executive Officer | 364.19K | Conversion of Exercise of derivative security |
2024-02-12 | FASOLO PETER M | Officer | 112.08K | Conversion of Exercise of derivative security |
2024-02-12 | HAIT WILLIAM | Officer | 38.65K | Conversion of Exercise of derivative security |
2024-04-30 | REED JOHN C | Officer | 11.58K | Conversion of Exercise of derivative security |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Group Inc | 247.48M | 40.96B | 9.52% |
2023-06-29 | Blackrock Inc. | 199.34M | 33.00B | 7.67% |
2023-06-29 | State Street Corporation | 141.83M | 23.48B | 5.46% |
2023-06-29 | Geode Capital Management, LLC | 49.70M | 8.23B | 1.91% |
2023-06-29 | Morgan Stanley | 41.67M | 6.90B | 1.60% |
2023-06-29 | JP Morgan Chase & Company | 31.78M | 5.26B | 1.22% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 81.05M | 13.42B | 3.12% |
2023-06-29 | Vanguard 500 Index Fund | 61.87M | 10.24B | 2.38% |
2023-05-30 | Fidelity 500 Index Fund | 29.26M | 4.54B | 1.13% |
2023-08-30 | SPDR S&P 500 ETF Trust | 26.52M | 4.29B | 1.02% |
2023-06-29 | Vanguard Index-Value Index Fund | 22.57M | 3.74B | 0.87% |
2023-08-30 | iShares Core S&P 500 ETF | 22.52M | 3.64B | 0.87% |
Dividend | Date |
---|---|
1.24 | 2024-05-20 |
1.19 | 2024-02-16 |
1.19 | 2023-11-20 |
1.19 | 2023-08-25 |
1.19 | 2023-05-22 |
1.13 | 2023-02-17 |
Split | Date |
---|---|
2 : 1 | 2001-06-13 |
2 : 1 | 1996-06-12 |
2 : 1 | 1992-06-10 |
2 : 1 | 1989-05-11 |
3 : 1 | 1981-05-19 |
3 : 1 | 1970-05-18 |
$JNJ Huge earning expected to beat tomorrow
$JNJ Offcourse, Results going to be beating estimate like Q1 and Q2. MarketBeat, stckpro, and all analyst say Buy or hold. Not to be sold.
Holding and recommend hold to see gap up tomorrow expecting 162+
$JNJ Results going to be amazing
Easy $162-$165 BUY this Dip
$JNJ Results going to be Amaziinng
Be ready to see $163-168 on Wednesday
$JNJ earnings next week
Expecting easy $155-160
$JNJ should have gotten to $149 as market move upside.. Hope it’s going to be there by EOD
Finally a chance to check vaccine results!! Sept 27th mark your calendar!! GO BNTX/PFE! https://www.google.com/amp/s/www.bloombergquint.com/amp/coronavirus-outbreak/pfizer-s-covid-vaccine-trial-plan-may-beat-rivals-to-early-look
I’m out. All the “extra” shares were at such a terrible price, I can’t make money, I’ll reinvest
Am I the only person who caught trump basically say jnj and Pfizer will soon have vaccine wasn’t that like a giveaway how are they tanking
$JNJ She’s gonna blow !!
Jnj$ wtf
where is 150 damn
why is down
Pou Asus: what more info do u have about Janssen Coronavirus vaccine’s pioneering design. Ty.
How many knew that Ocugen had a partnership which contractually GUARANTEES them revenues from Covid19 Antibody Testing?
(re: page 22 of annual report):
https://www.sec.gov/Archives/edgar/data/1372299/000110465920053502/tm2017927-1_10ka.htm
Collaboration with Advaite, Inc.
In April 2020, the Company entered into an agreement with Advaite, Inc., (Advaite) to provide certain support services for Advaite's development of a diagnostic test kit that is designed to detect antibodies to COVID-19. ...{Ocugen}... will receive tiered royalty payments based on cumulative net sales of the test kit.
The projected market for Covid diagnostic testing is $61B AND GROWING!
MORE IMPORTANTLY Advaite is NOW MOVING on Covid Antibody Testing!
https://www.linkedin.com/mwlite/company/advaite
*
The BEAUTY here:
NOBODY KNOWS Ocugen will be collecting potentially BILLION$ in COVID DIAGNOSTICS revenue! They NEVER did a PRESS RELEASE!
$SAVA - A second opinion
*
If you have been following Cassava and their Alzheimers drug PTI-125, you will know that 1 of 2 trial endpoints was not recently met, sending the stock down almost 80%. But, I think the exodus was premature. Here is why:
Per the companys press release, one endpoint WAS MET:
A secondary endpoint of CSF levels of IL1-beta, a core biomarker of neuroinflammation from baseline to day 28, was met, Cassava said. The drug was also found to be safe and well-tolerated.
Per NIH, neuro inflammation is the CORE issue with Alzheimers:
Inflammation in Alzheimer's disease (AD) has emerged as a central pathology that likely plays a role in onset and progression of the disease
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214864/
Cycling back to Cassavas press release, they state:
CSF levels of IL1-beta, a core biomarker of neuroinflammation ... was met
To reiterate the NIH definition, Neuro Inflammation is core to the onset and progression of Alzheimers. At some point, Cassava IS going to cycle back around to the secondary endpoint (neuro inflammation), and realize that ALONE constitutes an ALZHEIMER DRUG THAT WORKS.
In this case, traders were SO tuned into the word miss that they MISSED something EXTREMELY IMPORTANT -> The efficacy of PTI-125 towards Neuro Inflammation, in Alzheimers (ALONE), makes it A BLOCKBUSTER DRUG!
$SAVA - A second opinion
*
If you have been following $SAVA and their Alzheimers drug PTI-125, you will know that 1 of 2 endpoints was not recently met, sending the stock down almost 80%. But, I think the exodus was premature. Here is why:
Per the companys press release, one endpoint WAS MET:
A secondary endpoint of CSF levels of IL1-beta, a core biomarker of neuroinflammation from baseline to day 28, was met, Cassava said. The drug was also found to be safe and well-tolerated.
Per NIH, here is the CORE issue with Alzheimers:
Inflammation in Alzheimer's disease (AD) has emerged as a central pathology that likely plays a role in onset and progression of the disease
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214864/
Cycling back to Cassavas press release, they state:
CSF levels of IL1-beta, a core biomarker of neuroinflammation ... was met
To reiterate the NIH definition, Neuro Inflammation is core to the onset and progression of Alzheimers. At some point, the Cassava IS going to cycle back around to the secondary endpoint (neuro inflammation), and realize that ALONE constitutes an ALZHEIMER DRUG THAT WORKS.
In this case, traders were SO tuned into the word miss that they MISSED something EXTREMELY IMPORTANT. That the efficacy of PTI-125 towards Neuro Inflammation, in Alzheimers (ALONE), makes it A BLOCKBUSTER DRUG!
pepcid being tried for covid-19 distributed by jnj owned by bhc